MX2021012612A - Compuesto de fenilmetilpirazolona que tiene una nueva forma cristalina y metodo para producirlo. - Google Patents
Compuesto de fenilmetilpirazolona que tiene una nueva forma cristalina y metodo para producirlo.Info
- Publication number
- MX2021012612A MX2021012612A MX2021012612A MX2021012612A MX2021012612A MX 2021012612 A MX2021012612 A MX 2021012612A MX 2021012612 A MX2021012612 A MX 2021012612A MX 2021012612 A MX2021012612 A MX 2021012612A MX 2021012612 A MX2021012612 A MX 2021012612A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- phenylmethylpyrazolone
- producing same
- crystal form
- novel crystal
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 4
- -1 Phenylmethylpyrazolone compound Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000004458 analytical method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002858 crystal cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención se refiere a un compuesto de fenilmetilpirazolona y a un método para producirlo, teniendo dicho compuesto una nueva forma cristalina que corresponde a parámetros determinados por el método de análisis de difracción de rayos X en polvo, en donde los parámetros de las celdas cristalinas corresponden a: a (Å ) - 10,244 (6) Å, b (Å) - 11,198 (5) Å, c (Å) - 15,911 (9) Å, ß ° - 94,95 (3)°, VÅ 3 - 1821 (3) Å3. Los ángulos 2T para los patrones de difracción de cristales corresponden a: 4,73°; 5,98°; 9,11°; 9,94°; 11,45°; 14,74°; 15,85°; 17,09°; 21,60°. Los espaciamientos interplanares de los cristales corresponden a: 8,09 Å; 6,42 Å; 4,58 Å; 3,97 Å; 3,12 Å; 2,79 Å; 2,58 Å; 2,37; 1,99 Å. Esta invención se refiere a un compuesto de fenilmetilpirazolona que tiene una forma cristalina, que corresponde a los parámetros determinados por el método de análisis de difracción de rayos X en polvo de Debye-Scherer, en donde los parámetros de las celdas cristalinas corresponden a: a (Å) - 10,244 (6) Å, b (Å) - 11,198 (5) Å, c (Å) - 15,911 (9) Å, ߺ - 94,95 (3)º, VÅ3 - 1821 (3) Å3. Los ángulos 2T para los patrones de difracción de cristales corresponden a: 4,73º; 5,98º; 9.11º; 9,94º; 11,45º; 14,74º; 15,85º; 17,09º; 21.60º. Las distancias interplanares de los cristales corresponden a: 8,09 Å; 6,42 Å; 4,58 Å; 3,97 Å; 3,12 Å; 2,79 Å; 2,58 Å; 2,37; 1,99 Å. Un proceso de obtención de dicho compuesto en forma de cristal, implica la recristalización de la sustancia obtenida y contiene las siguientes etapas: i) disolver los cristales obtenidos en el proceso de síntesis en etanol mediante calentamiento a 45 °C a reflujo; ii) filtrar la solución resultante, sin enfriar a través de un filtro de material inerte; iii) enfriar la solución a 5 °C para formar un precipitado (cristales); iv) lavar los cristales obtenidos con acetato de etilo para eliminar las impurezas; v) secar los cristales lavados en un evaporador rotatorio al vacío.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA201904026A UA121366C2 (uk) | 2019-04-17 | 2019-04-17 | Сполука фенілметилпіразолону, що має нову кристалічну форму, та спосіб її одержання |
| PCT/IB2019/061397 WO2020212748A1 (ru) | 2019-04-17 | 2019-12-27 | Соединение фенилметилпиразолона, имеющее новую кристаллическую форму, и способ его получения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012612A true MX2021012612A (es) | 2022-11-10 |
Family
ID=71115919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012612A MX2021012612A (es) | 2019-04-17 | 2019-12-27 | Compuesto de fenilmetilpirazolona que tiene una nueva forma cristalina y metodo para producirlo. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220242827A1 (es) |
| EP (1) | EP3957628A1 (es) |
| CN (1) | CN113365983A (es) |
| BR (1) | BR112021017855A2 (es) |
| CL (1) | CL2021002697A1 (es) |
| MX (1) | MX2021012612A (es) |
| PE (1) | PE20220501A1 (es) |
| UA (1) | UA121366C2 (es) |
| WO (1) | WO2020212748A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113072502A (zh) * | 2021-03-02 | 2021-07-06 | 山东罗欣药业集团恒欣药业有限公司 | 一种脑保护剂及其关键杂质的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102060771A (zh) * | 2009-11-18 | 2011-05-18 | 南京长澳医药科技有限公司 | 一种依达拉奉晶型及其制备方法 |
| CN102351795A (zh) * | 2011-08-02 | 2012-02-15 | 天津市嵩锐医药科技有限公司 | 一种稳定晶型的依达拉奉化合物 |
| CN102643234B (zh) * | 2012-04-02 | 2015-09-30 | 浙江大学 | 依达拉奉多晶型物及其制备方法 |
| CN102766097B (zh) * | 2012-06-27 | 2014-11-05 | 江苏正大丰海制药有限公司 | 一种依达拉奉a型晶体及其制备方法 |
| CN103833640B (zh) * | 2012-11-16 | 2016-06-22 | 国药集团国瑞药业有限公司 | 一种依达拉奉晶体、其制备方法及其应用 |
| CN103319409B (zh) * | 2013-07-12 | 2015-09-09 | 四川省惠达药业有限公司 | 一种依达拉奉化合物、其药物组合物及其制备方法 |
| CN104163801B (zh) * | 2014-01-27 | 2016-08-24 | 洪军 | 一种依达拉奉化合物 |
| CN105753785B (zh) * | 2016-03-23 | 2018-03-02 | 海南合瑞制药股份有限公司 | 一种依达拉奉的晶型及其制备方法 |
-
2019
- 2019-04-17 UA UAA201904026A patent/UA121366C2/uk unknown
- 2019-12-27 MX MX2021012612A patent/MX2021012612A/es unknown
- 2019-12-27 EP EP19850821.0A patent/EP3957628A1/en not_active Withdrawn
- 2019-12-27 PE PE2021001681A patent/PE20220501A1/es unknown
- 2019-12-27 CN CN201980090225.1A patent/CN113365983A/zh active Pending
- 2019-12-27 WO PCT/IB2019/061397 patent/WO2020212748A1/ru unknown
- 2019-12-27 BR BR112021017855A patent/BR112021017855A2/pt not_active Application Discontinuation
-
2020
- 2020-10-22 US US17/601,085 patent/US20220242827A1/en active Pending
-
2021
- 2021-10-14 CL CL2021002697A patent/CL2021002697A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3957628A1 (en) | 2022-02-23 |
| WO2020212748A1 (ru) | 2020-10-22 |
| BR112021017855A2 (pt) | 2021-11-30 |
| CL2021002697A1 (es) | 2022-08-19 |
| US20220242827A1 (en) | 2022-08-04 |
| UA121366C2 (uk) | 2020-05-12 |
| CN113365983A (zh) | 2021-09-07 |
| PE20220501A1 (es) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20094576B (en) | New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| GEP20094577B (en) | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| UA83720C2 (ru) | Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит | |
| MY183277A (en) | Zeolite membrane, production method therefor, and separation method using same | |
| JO3178B1 (ar) | النموذج السادس البلوري الجديد من مركب الاغوميلاتين وطريقة تحضيره وتحضير المركبات الصيدلانية المحتوية عليه | |
| EA201070774A1 (ru) | Цеолит типа lsx с контролируемой гранулометрией | |
| BRPI0519913A2 (pt) | métodos de produzir titánio metálico, de fabricar pó de titánio metálico, de preparar um artefato de titãnio e de recuperar titánio, e, pó de titánio | |
| BR112015031174A2 (pt) | processo para a preparação de butadieno | |
| MX2021012612A (es) | Compuesto de fenilmetilpirazolona que tiene una nueva forma cristalina y metodo para producirlo. | |
| CY1117753T1 (el) | Κρυσταλλικη μορφη του αλατος αργινινης της περινδοπριλης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις οι οποιες την περιεχουν | |
| PH12016501636A1 (en) | Method for producing seed crystals used for producing hydrogen-reduced nickel powder | |
| PH12021550790A1 (en) | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| ZA202200283B (en) | Method for producing a metastable crystal modification of n-(aminoiminomethyl)-2-aminoethanoic acid (iv) | |
| MX2021012680A (es) | Metodos para la produccion de monohidrato de l-glufosinato de amonio cristalino. | |
| NO20075094L (no) | Fremstilling av ammoniumdinitroamid(ADN)krystaller, krystallene og de energirike sammensetninger som inneholder disse krystallene | |
| EP4017622A4 (en) | GRANULES OF POLYHALOGENITE, POTTA ASH AND AMMONIUM SULFATE AND PROCESS FOR THEIR PRODUCTION | |
| MY182015A (en) | Process for preparing a boron containing zeolitic material having mww framework stracture | |
| BR112014014762A8 (pt) | método para preparação de cisteína ou de um derivado desta usando uma nova o-fosferina sulfidrilase | |
| WO2018153381A9 (zh) | 一种适用于工业化生产的高纯度异硫氰酸酯类化合物制备方法 | |
| EA201000464A1 (ru) | Способ получения очищенного синтез-газа из синтез-газа, содержащего следовые количества примеси сернистых соединений, с помощью металлорганической структуры | |
| BR112017028639A2 (pt) | composto novo que se liga especificamente ao receptor ampa, composição farmacêutica e método para a produção do mesmo | |
| CL2004000574A1 (es) | Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion. | |
| MX2022002941A (es) | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. | |
| ZA200800138B (en) | Process for the preparation of crystalline perindopril | |
| WO2009004791A1 (ja) | 単結晶シンチレータ材料およびその製造方法 |